Myriam Heiman

Dr. Heiman’s expertise is in the development of genetic and biochemical methods for the study of the mammalian nervous system, as well as the study of basal ganglia circuits and their dysfunction in disease. She received a B.A. in molecular biology from Princeton University, a Ph.D. in cell biology from the Johns Hopkins University, and post-doctoral training at the Rockefeller University. The focus of her research group is to understand the molecular basis of nerve cell function and dysfunction in CNS diseases and disorders, seeking to understand what combination of cell autonomous and non-cell autonomous mechanisms leads to vulnerability in these diseases and disorders, as well as which cell types are most important in considering the actions of CNS-acting drugs such as antipsychotic drugs and drugs involved in substance use disorders.